COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02151864
Recruitment Status : Completed
First Posted : May 30, 2014
Last Update Posted : March 5, 2019
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jason K. Sicklick, M.D., University of California, San Diego

Brief Summary:
The purpose of this study is to test the safety and determine the maximum safe dose of an experimental drug called LDE225 (hedgehog inhibitor) in people with liver cancer. We have identified hedgehog dysregulation as a novel mechanism for hepatocarcinogenesis and hepatic fibrosis/cirrhosis. Therefore, we hypothesize that the hedgehog inhibitor may be an ideal drug target for treating both hepatocellular carcinoma (HCC) and Child-Pugh A cirrhosis (CPA).

Condition or disease Intervention/treatment Phase
Hepatocellular Carcinoma Cirrhosis Drug: LDE225 Phase 1

Detailed Description:

This is an open-label, single institution, Phase I, 3+3 dose escalation study of LDE225 in patients with advanced or metastatic hepatocellular carcinoma and Child-Pugh A Cirrhosis who are intolerant to sorafenib. The investigational treatment cycle (21 days) will consist of daily oral LDE225.

Dose escalation will be performed in serial patient cohorts. Up to six patients can be studied at each dose level. Safety and clinical data will be tabulated and the decision to open the next cohort level will be the responsibility of the principal investigator. Dose escalation will be based on the dose-limiting toxicities encountered through Day 42 of investigational treatment.

Patients will be dosed on a flat scale of daily dosing of LDE225 prescribed by the dose cohort.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
Actual Study Start Date : July 2014
Actual Primary Completion Date : December 2016
Actual Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Sonidegib

Arm Intervention/treatment
Experimental: LDE225
LDE225 200mg-800mg oral daily
Drug: LDE225
LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
Other Name: hedgehog inhibitor

Primary Outcome Measures :
  1. Rate of dose limiting toxicities [ Time Frame: occurring within 42 days of investigational treatment ]
    A dose limiting toxicity is a clinically significant adverse event (AE) occurring within 42 days of investigational treatment that is considered by the investigator to be possibly, probably, or definitely related to LDE225.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 years or older
  • Pathological confirmation of advanced or metastatic HCC
  • HCC not amenable to surgical resection, liver transplantation, chemoembolization, or ablation therapy
  • Patients with Child-Pugh A and Child-Pugh B7 (if due to low albumin but not elevated INR or bilirubin) cirrhosis are allowed.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • At least one measurable site of disease (as defined by Response Evaluation Criteria in Solid Tumors)
  • Patients with adequate bone marrow, liver and renal function
  • Inability to tolerate first-line treatment with sorafenib
  • Patient amenable to liver tumor biopsy

Exclusion Criteria:

  • Child-Pugh B or Child-Pugh C cirrhosis
  • Patients with known Gilbert's Syndrome
  • Ongoing alcohol use or abuse defined as > an average of 2 alcoholic beverages daily
  • Patients who have had major surgery within 4 weeks of initiation of study medication
  • Patients with known brain metastases
  • Patients with concurrent uncontrolled medical conditions that may interfere with their participation in the study
  • Patients with known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness
  • Patients with Hepatitis B and/or Hepatitis C infection are excluded if they are on any of the following viral suppressive agents: boceprevir (Victrelis), ribavirin (Rebetol, Ribatab, Ribasphere), telaprevir (Incivek)
  • Patients unable to take oral drugs or with lack of physical integrity of the upper gastrointestinal tract or known malabsorption syndromes
  • Patients who have previously been treated with systemic LDE225 or with other Hh pathway inhibitors
  • Patients who have neuromuscular disorders or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis
  • Patients who are planning on embarking on a new strenuous exercise regimen after initiation of study treatment
  • Patients who have taken part in an experimental drug study within 4 weeks of initiating study treatment with LDE225
  • Patients who are receiving other anti-neoplastic therapy concurrently or within 2 weeks of starting study treatment with LDE225
  • Patients who are receiving any anti-coagulation or anti-platelet therapy
  • Patients who are receiving treatment with medications known to be strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4/5) or drugs metabolized by cytochrome P450 2B6 (CYP2B6) or cytochrome P450 2C9 (CYP2C9) that have narrow therapeutic index, and that cannot be discontinued before starting study treatment with LDE225
  • Impaired cardiac function or clinically significant heart disease
  • Patients with contraindications for MRI and/or MRI contrast agents
  • Pregnant or nursing (lactating) women
  • Women of child-bearing potential must use highly effective contraception during the study and through 6 months after the final dose of study treatment
  • Sexually active males who are unwilling to use a condom during intercourse while taking drug and for 6 months after stopping investigational medications and agree not to father a child in this period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02151864

Layout table for location information
United States, California
UCSD Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
Jason K. Sicklick, M.D.
Novartis Pharmaceuticals
Layout table for investigator information
Principal Investigator: Jason K. Sicklick, MD University of California Medical Center

Layout table for additonal information
Responsible Party: Jason K. Sicklick, M.D., Assistant Professor, Surgery, University of California, San Diego Identifier: NCT02151864    
Other Study ID Numbers: 131053
First Posted: May 30, 2014    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: March 2019
Keywords provided by Jason K. Sicklick, M.D., University of California, San Diego:
liver cancer
Child-Pugh A
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Liver Cirrhosis
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Pathologic Processes